• Publications
  • Influence
Risk factors for hepatocellular carcinoma: Synergism of alcohol with viral hepatitis and diabetes mellitus
A significant synergy between heavy alcohol consumption, hepatitis virus infection, and diabetes mellitus may suggest a common pathway for hepatocarcinogenesis in high‐risk individuals. Expand
Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: A Hospital-Based Case–Control Study
Liver cirrhosis and chronic HCV infection are possible risk factors for ICC but not ECC, and heavy alcohol consumption is a risk factor for both ICC and ECC. Expand
Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
PIAF is active in hepatocellular carcinoma despite considerable hematological toxicity, and complete pathological remission is possible with this systemic combination, Apparently, persistent radiological lesions may still represent complete pathological resolution of active disease. Expand
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma
The goal of the current study was to evaluate the efficacy and toxicity of capecitabine in patients with nonresectable hepatobiliary carcinoma.
The Role of Hepatitis C in Hepatocellular Carcinoma: A Case Control Study Among Egyptian Patients
Both HCV and hepatitis B virus infection increase the risk of HCC in Egyptian patients, whereas isolated Schistosoma infection does not. Expand
Colorectal carcinoma and brain metastasis: Distribution, treatment, and survival
Surgical removal of colorectal metastatic brain lesions results in significantly increased survival time, regardless of the status of the noncerebral systemic disease. Expand
Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge.
Hepatic arterial chemoembolization provided effective palliation, with good-quality survival among 46% of patients with ocular melanoma metastatic to the liver, and treatment-related morbidity was short-lived. Expand
Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma.
UFT 300 mg/m2/d plus oral leucovorin 150 mg/d administered for 28 days demonstrated significant activity against metastatic colorectal carcinoma and was well tolerated and devoid of the neutropenia or significant oral mucositis that complicates intravenous schedules of fluorouracil (5-FU) plus leucavorin. Expand
OncoSurge: a strategy for improving resectability with curative intent in metastatic colorectal cancer.
A therapeutic decision model is created identifying individual patient resectability, recommending optimal treatment strategies and may also be used for medical education. Expand
Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
Continuous IV FU and thrice-weekly SC rIFNalpha2b are an effective treatment, especially for FLHCC, and may have a neoadjuvant role in this disease. Expand